Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· March 3, 2026

Stocks Sink as Crude Oil Surge Rattles Markets

View original at nasdaq.com
Stocks Sink as Crude Oil Surge Rattles Markets The S&P 500 Index ($SPX) (SPY) today is down -2.18%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -2.27%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -2.37%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We will set fire to any ship attempting to pass through the Strait of Hormuz

    80% confidence

  • Combat operations against Iran could last for weeks until all objectives were completed

    80% confidence

  • Additional Fed interest rate cuts will be warranted if inflation slows further once most of the impact of tariffs has passed

    80% confidence

  • The real-time risk premium for crude oil is $18/bbl, corresponding to the impact of a six-week full halt to tanker traffic in the Strait of Hormuz

    80% confidence

  • Inflation has been above the Fed's objective for nearly five years now, so I don't think we have room to be complacent

    80% confidence

  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings are expected to increase by 4.6%

    80% confidence

  • Iran's leaders should capitulate

    80% confidence

  • S&P earnings growth is expected to climb by 8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com